



Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

Massimo Carlo Mauri¹ · Silvia Paletta¹ · Chiara Di Pace¹ · Alessandra Reggiori¹ ·
Giovanna Cirigliaro¹ · Isabel Valli² · Alfredo Carlo Altamura¹

Published online: 19 June 2019
© Springer Nature Switzerland AG 2019

Correction to: Clin Pharmacokinet (2018) 57:1493–1528
<https://doi.org/10.1007/s40262-018-0664-3>

Page 1517, Section 16.1, para 1, lines 1–3 which previously read:

The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242].

Should read:

The pharmacokinetics of CRP was tested in small short-term studies in healthy volunteers [235] and also in subjects with schizophrenia [242], with similar results.

Page 1517, Section 16.1, para 1, lines 4–6 which previously read:

Cariprazine is rapidly absorbed, reaching peak concentrations between 3 and 4 h after oral dosing in healthy subjects.

Should read:

Cariprazine reached peak plasma concentrations between 3 and 4 h after oral dosing in healthy subjects.

The original article can be found online at <https://doi.org/10.1007/s40262-018-0664-3>.

✉ Massimo Carlo Mauri
maurimc@policlinico.mi.it

¹ Clinical Psychopharmacology Unit, Department of Neuroscience and Mental Health, Clinical Psychiatry, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via F.Sforza 35, Milan 20122, Italy

² Department of Psychosis Studies, King's College London, London, UK

Page 1517, Section 16.1, para 2, lines 1–5 which previously read:

Its pharmacokinetics were linear in terms of AUC but maximum concentrations were more than proportional within the dose range from 3 to 5 mg in healthy subjects. Mean half-life was 2–5 days (1.5–12.5 mg/day) in the subjects with schizophrenia [242].

Should read:

Its pharmacokinetics were linear in terms of AUC but maximum concentrations were more than proportional within the single dose range from 0.5 to 2.5 mg in healthy subjects. Mean half-life was 2–5 days (1.5–12.5 mg/day) in the subjects with schizophrenia [235].

Page 1518, Section 16.1, para 2, lines 8–11 which previously read:

Additionally, the mean concentrations of DCRP and DDCRP were approximately 30 and 40% in the patients, respectively, of CRP concentrations by the end of 12 weeks of treatment [242].

Should read:

Additionally, the mean concentrations of DCRP and DDCRP were approximately 30 and 400% in the patients, respectively, of CRP concentrations by the end of 12 weeks of treatment [242].

Page 1518, Table 8, column 1, row 2, which previously read:

Actavis 2015 [243]

Should read:

Actavis 2015 [242]

Page 1518, Table 8, column 2, row 2, which previously
read:

6

Should read:

8

Page 1518, Table 8, column 6, row 3, which previously
read:

32–49

Should read:

10–22.7